ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
1/1
2 files

Rationalizing Viral Drug Target Identification Using Computational Approaches : The SARS-CoV-2 Spike Glycoprotein S Case Study

preprint
submitted on 18.11.2020, 09:45 and posted on 19.11.2020, 04:48 by Petr Popov, Pavel Buslaev, Igor Kozlovskii, Mark Zaretskii, Dmitry Karlov, Alexander Morozov

COVID-19 emphasized the need for fast reaction tools to fight global biological threats such as viruses. Rapid drug discovery is one of the strategies for efficient social response. The success of a drug discovery campaign critically depends on the selected drug target, and the wrong target nullifies all the efforts to develop a drug. Viral drug target identification is a challenging problem, and computational methods can reduce the number of candidate targets. Here we present a structure-based approach to identify vulnerable regions in viral proteins that comprise drug binding sites. To detect promising binding sites, we take into account protein dynamics, accessibility, and mutability of the binding site, coupled with the putative mechanism of action of a drug. Applying to the SARS-CoV-2 Spike Glycoprotein S, we observed conformation- and oligomer-specific glycan-free binding site that is proximal to the receptor binding domain and comprises topologically important amino acid residues. Molecular dynamics simulations of Spike in complex with drug-like molecules docked into the binding sites revealed shifted equilibrium towards the inactive conformation compared to the ligand-free simulations. Small molecules targeting this binding site could prevent the closed-to-open conformational transition of the Spike protein, thus, allosterically inhibit the interaction with the human angiotensin-converting enzyme 2 receptor.

History

Email Address of Submitting Author

p.popov@skoltech.ru

Institution

iMolecule, CDISE, Skolkovo Institute of Science and Technology, Moscow, Russia

Country

Russia

ORCID For Submitting Author

0000-0003-3745-7154

Declaration of Conflict of Interest

The authors declare no conflict of interest

Exports